Dr. Chris Thompson is Professor of Medicine at Harvard Medical School and a practicing weight loss doctor. He is also the founder of Bariendo, a network of clinics that provide ESG, a non-surgical way to lose 20% of body weight or more.
Researchers modeled the costs and effectiveness of weight-loss drug Wegovy (semaglutide) and a minimally-invasive procedure called endoscopic sleeve gastroplasty.
The goal of this study was to figure out if ESG was cost-effective. However, with these medications [GLP-1s] becoming so prominent and being so expensive, it seemed like the expense [of treating patients with these drugs] could be astronomical.
Obesity is a disease. It’s time we treated it like one.